Posts Tagged ‘Shire’

Big Pharma’s Next Big Thing: Antipsychotic Medicines for Preschoolers

Thursday, September 9th, 2010

BNET

By Jim Edwards

Dr. Joan Luby, the preschool depression researcher at the center of a New York Times article that failed to mention her past research was funded by Johnson & Johnson (JNJ), Shire (SHPGY) and AstraZeneca (AZN), is currently testing the antipsychotic Risperdal on autistic children aged 30 months to 5 years old, according to the ClinicalTrials.gov database. Although the study is not funded by Janssen, the unit of J&J that makes Risperdal, it nonetheless typifies a new field of drug research: The use of mood-altering pharmaceuticals on the very, very young.

The NYT piece investigated the development of preschool depression as a diagnosis. Slate, like me, found it surprising that the author did not believe Big Pharma’s interest in the field was relevant. Minyanville thought the same thing. Such research is controversial. In November 2008, the FDA said antipsychotic drugs were over-used in children and that more should be done to discourage doctors from treating unruly kids with powerful drugs.

Luby — who also believes that certain antidepressants may be effective in children, according to this press release — is just one researcher looking at extending the use of antipsychotics to very young kids. Here’s a study on Lithium vs. Risperdal in kids aged 7 and up. And here’s a similar trial on kids aged 6 and up. GlaxoSmithKline (GSK) is currently testing Paxil on 7-year-olds despite that medicine’s well-document propensity to trigger suicides in young patients.

The reason the FDA has warned against use of these drugs in kids is twofold: First, many of these products are not approved for use in children. Risperdal — the product in the Luby study of 30-month olds — is only approved for use in autistic children older than 5; and for schizophrenics older than 13. Eli Lilly (LLY)’s competing antipsychotic Zyprexa is not indicated for anyone below the age of 13.

Read the rest of this article here http://www.bnet.com/blog/drug-business/big-pharma-8217s-next-big-thing-antipsychotic-medicines-for-preschoolers/5624?tag=content;drawer-container

To see what side effects doctors, pharmacists,  health care providers and consumers have reported to the US FDA regarding antipsychotics and antidepressants on children (including 0-1 year olds) search CCHR’s decrypted FDA Medwatch reports here http://www.cchrint.org/psychdrugdangers/medwatch_psych_drug_adverse_reactions.php

« Return to news items


Share

Meet the Queen of “Preschool Depression” — and Her Drug Company Backers

Monday, August 30th, 2010

by Jim Edwards

BNET August 30, 2010

The NYT Sunday magazine crowned Dr. Joan Luby as the queen of preschool depression this weekend, but failed to mention that Luby has taken cash from Johnson & Johnson (JNJ), Shire (SHPGY) and AstraZeneca (AZN) to study using atypical antipsychotics in young children. The article is significant because of the outsize role that the Times magazine plays in creating and naming new social trends. (Remember when you suddenly figured out that carbs make you fat but fatty meat doesn’t? That was the NYT mag.)

In this case, the phenomenon is depression in children as young as three years old, and the trend is to treat it with drugs such as Risperdal, Zyprexa, Adderall and Seroquel. The article, by Pamela Paul, provides a useful roadmap into how parenting will be medicalized by Big Pharma:

“The idea is very threatening,” says Joan Luby, a professor of child psychiatry  at Washington University School of Medicine, … “In my 20 years of research, it’s been slowly eroding,” Luby says of that resistance. “But some hard-core scientists still brush the idea off as mushy or psychobabble, and laypeople think the idea is ridiculous.”

The “ridiculous” layperson who first pointed out that Luby had written medical journal articles urging the use of antipsychotics on preschool children without declaring her drug company payments was me. Luby was a paid speaker for AstraZeneca in 2003-2004 (AZ makes Seroquel); she received $2019 in a for a consultancy from Shire in 2004 (Shire makes Adderall and Vyvanse); and prior to 2006 she received grant/research support from Janssen, the unit of J&J that markets Risperdal. Luby is also a member of a group of scientists who want greater study of potential new uses for psychiatric drugs in young children. That group has ties to 16 different drug companies. Some of these drugs have dangerous side effects.

The Archives of General Psychiatry (published by the American Medical Association) said it would investigate how Luby failed to disclose her past ties when it published “Preschool Depression,” a study she did on 3- to 6-year-olds. Joseph Coyle, the editor of the AGP, did not immediately respond to an email requesting an update on its Luby probe. (The American Psychiatric Association, which publishes the American Journal of Psychiatry, has chosen to ignore the issue.)

Read the rest of this article here:  http://www.bnet.com/blog/drug-business/meet-the-queen-of-8220preschool-depression-8221-8212-and-her-drug-company-backers/5595

To read about other pharma funded psychiatrists promoting a psycho/pharma agenda  read Shrinks For Sale – The Corrupt Alliance of the Psychiatric-Pharmaceutical Industry by CCHR   http://www.cchrint.org/cchr-issues/the-corrupt-alliance-of-the-psychiatric-pharmaceutical-industry/

Also read DSM Panel Members Still Getting Pharma Funds by CCHR http://www.cchrint.org/2010/05/21/dsm-panel-members-still-getting-pharma-funds/

« Return to news items


Share

Father sues Harvard over son’s suicide – 3 psychiatric drugs prescribed him were all documented to cause suicide

Saturday, December 5th, 2009

Thom Weidlich
Bloomberg.com
December 5, 2009

The father of a Harvard College sophomore who killed himself in 2007 sued the school’s president and fellows for wrongful death, alleging the institution’s health service prescribed drugs known to increase suicide risk.

John B. Edwards II of Wellesley, Massachusetts, sued on behalf of the estate of his son, known as Johnny, in state court in Middlesex County on Dec. 2. A doctor and nurse employed by Harvard simultaneously prescribed skin, antidepressant and attention-deficit disorder drugs linked to suicide and other side effects, according to the complaint.

“Three of these drugs have risks associated with heightened suicidality,” the father’s lawyer alleged in the complaint. “All four drugs have significant side effects.”

Harvard College in Cambridge, Massachusetts is the undergraduate school of Harvard University, whose $26-billion endowment is the world’s largest academic fund.

“The care he received at Harvard University Health Services was thorough and appropriate and he was monitored closely by its physicians and allied health specialists,” Harvard said yesterday in an e-mailed statement. “Similar complaints previously have been filed with the Board of Registration in Medicine, the Board of Registration in Nursing and the Board of Registration in Pharmacy, and in all three instances the complaints were dismissed upon review.”

Read entire article:  http://www.bloomberg.com/apps/news?pid=20601103&sid=aIlr9YQwCSnY

« Return to news items


Share

Psych journal “looks into” whether psychiatrist who endorsed antidepressants for preschoolers was getting Pharma $$

Thursday, September 10th, 2009

Jim Edwards
bnet.com
September 10, 2009

The journal Archives of General Psychiatry will “look into” whether an author who recommended antidepressants for preschoolers failed to disclose her financial ties to Johnson & Johnson, AstraZeneca and, companies which make such drugs, according to Philip Dawdy of Furious Seasons.

Dr. Joan Luby,  a professor of child psychiatry at the Washington University School of Medicine in St. Louis, has authored several papers asserting that children as young as three years old can suffer from depression and bipolar disorder, and that treatment with antidepressants and antipsychotics may be appropriate. In a recent paper of the AGP, she wrote:

Preschool depression, similar to childhood depression, is not a developmentally transient syndrome but rather shows chronicity and/or recurrence.

She did not disclose any ties to industry. However, Luby has past ties to J&J’s Janssen unit, AZ and Shire (makers of Risperdal, Seroquel and Adderall XR, respectively).

Read entire article: http://industry.bnet.com/pharma/10004189/agp-to-probe-undisclosed-industry-ties-of-doc-who-recommends-antidepressants-for-3-year-olds/

« Return to news items


Share

No Surprise: Psychiatrist pushing “Depression” testing for 3-yr-olds connected to three drug companies

Monday, August 17th, 2009

Martha Rosenberg
The Epoch Times
August 17, 2009

Try to access the Web site of the Archives of General Psychiatry, and you may have to abide an ad for the antidepressant Pristiq before you can enter. (JAMA and its Archives Journals “do not endorse the advertised product,” you’ll be assured.)

But look for a pharma affiliation for the author of the article “Preschool Depression,” Joan L. Luby, M.D., in the August issue, and you’ll be told no “financial disclosure” was reported. Not that “Dr. Luby has received grant/research support from Janssen, has given occasional talks sponsored by AstraZeneca, and has served as a consultant for Shire Pharmaceutical,” as a 2006 article in Journal of the American Academy of Child and Adolescent Psychiatry says.

Even though the pharmaceutical industry has 27 million Americans—10 percent of the population—on antidepressants, thanks to direct to consumer advertising, it is looking for depression in preschoolers. And guess what? It’s finding it!

Read entire article: http://www.theepochtimes.com/n2/content/view/21114/

« Return to news items


Share